AstraZeneca announce an interim dividend increased 3 cents to $1.06 per share. Ex-dividend date and record date 7th August which will be payable on 8th September.
Other financial highlights include:
* Total Revenue up 6%, with double-digit growth in Oncology and Rare Disease offsetting headwinds from Farxiga US loss of exclusivity and China volume-based procurement
* Core Operating profit and Core EPS increased 11%
* 30 approvals in major regions since Q4 2025 results
